Insider Trading Alert - Vertex Pharmaceuticals And 4 Others Traded By Insiders

Yesterday, July 5, 2013, 389 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $200.00 to $15,089,002.16.

Highlighted Stocks Traded by Insiders:

Vertex Pharmaceuticals (VRTX) - FREE Research Report

Mueller Peter who is EVP, Global R&D, CSO at VERTEX PHARM bought 254,938 shares at $38.41 per share for a total value of $13,525,842.90 on July 2, 2013. Following this transaction, the EVP, Global R&D, CSO owned 1.4 million shares meaning that the stake was boosted by 18.8% with the 254,938 share acquisition.

The shares most recently traded at $80.70, up $0.07, or 0.09% since the insider transaction. Historical insider transactions for Vertex Pharmaceuticals go as follows:

  • 4-Week # shares sold: 8,300
  • 12-Week # shares sold: 91,720
  • 24-Week # shares sold: 91,720

The average volume for Vertex Pharmaceuticals has been 2.6 million shares per day over the past 30 days. Vertex Pharmaceuticals has a market cap of $17.6 billion and is part of the health care sector and drugs industry. Shares are up 89.79% year to date as of the close of trading on Wednesday.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Currently there are 13 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRTX - FREE

TheStreet Quant Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Vertex Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Vertex Pharmaceuticals Could Be Headed Higher Once Again

Omeros Shares Lower After Completing Stock Offering, Juno Dips - Biotech Movers

10 High-Yielding Stocks to Own Ahead of a Surprising Late Summer Market Swoon

Vertex Pharmaceuticals: Looking East, West and to the Quants

Vertex Pharmaceuticals: Looking East, West and to the Quants